Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia

Abstract

Hyperlipidemia is a prevailing risk factor that leads to development and progression of atherosclerosis and consequently cardiovascular diseases. Several antihyperlipidemic drugs are having various disadvantages such as low water solubility and poor bioavailabilty due to presystemic gastrointestinal clearance. Thus, there is a considerable need for the development of efficient delivery methods and carriers. This review focuses on the importance and role of various nanoparticulate systems as carrier for antihyperlipidemic drugs in the treatment of hyperlipidemia. Some nanoparticle technology-based products are approved by FDA for effective treatment of hyperlipidemia, namely Tricor® by Abbott Laboratories (Chicago, IL, USA) and Triglide® by Skye Pharma (London, UK). Efforts to address each of these issues are going on, and should remain the focus on the future studies and look forward to many more clinical products in the future.

Flavonoids furom Coreopsis tinctoria adjust lipid metabolism in hyperlipidemia animals by down-regulating adipose differentiation-related protein

“…Here we investigate its effect on modulating the lipid metabolism. Hyperlipidemia is a lipid metabolic disease due to abnormal fat metabolism [ 8 ]. In this study, we use high fat diet by intragastric administration to set up a hyperlipidemia model in mice.…”

Development and characterization of floating spheroids of atorvastatin calcium loaded NLC for enhancement of oral bioavailability

“…ATS is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1-2 h. The absolute bioavailability of ATS (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism by the enzyme cytochrome P450-3A4 found in liver and intestine (Sharma et al 2014). Even though food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as measured by C max and area under the curve (AUC), LDL-C reduction is similar irrespective of whether LIPITOR is given with or without food.…”

Characterization and Cytotoxicity Evaluation of Biologically Synthesized Silver Nanoparticles from Albuca setosa Aqueous Bulb Extract

“…There are increasing reports on the synthesis of silver nanoparticles (AgNPs) from plant extracts. 10,11 This work therefore aimed to synthesize AgNPs using the aqueous bulb extracts of Albuca setosa, characterize and evaluate its antioxidant and antibacterial activities.…”